Author | n | EOA/EF | PtsCHD | | | | Mortality | | |
---|
| | | | Total | -CHD | +CR | -CR | +CR +CHD | -CR +CHD |
Connolly [3] | 52 | < 0.9/< 35 | 62% | 21% | | | | | |
Monin [5]* | 136 | < 0.8/< 35 | 40% | 14% | | 5% | 32% | 11% | 62% |
Powell [8] | 55 | < 0.75/< 30 | 36% | 18% | 3% | | | | |
Tarantini [9] | 52 | < 1.0/< 35 | 30% | 8% | | | | | |
Monin [10] | 30 | < 0.8/< 30 | 43% | 16% | | 8% | 50% | | |
Nishimura [15] | 21 | < 1.0/< 40 | 70% | 14% | | 14% | | | |
-
EOA/EF effective orifice area (cm2)/ejection fraction (%), PtsCHD proportion of patients with coronary heart disease, Mortality:-CHD patients without coronary heart disease, +CHD patients with coronary heart disease, -CR patients with no contraction reserve, +CR patients with contraction reserve, periop perioperative, n number of patients, * multicentre study